Experimental and Clinical Evaluation in Man of Hexamethonium (C6), A New Ganglionic Blocking Agent

摘要: In man, C6, a new ganglionic blocking agent (50 mg. intravenously) produced inhibition of the Valsalva, tiltback and cold pressor vasopressor responses. Marked increases in digital blood flow skin temperature with reflexes to "noxious" stimuli were consistently observed (room 70 F.). The increase was greater more lasting than following Priscoline or tetraethylammonium chloride. Except for severe postural hypotension, side effects minimal. Clinically drug may be useful evaluation sympathetic vasoconstriction peripheral vascular disease as well treatment acute neurogenic vasospasm.